Allergan and Mentor Group Fight for Breast Implant Market Share in Europe

Millennium Research Group’s New Marketrack Data Clearly Defines Changes in European Breast Implant Market Shares

TORONTO--(BUSINESS WIRE)-- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, Allergan and Mentor Group continue to compete head-to-head in Europe in the breast implant market, using a variety of tactics to gain share in various national markets. While Allergan is the market leader in most of the EU5, Mentor continues to lead in France, spurred by their acquisition of Perouse Plastie in 2007.

The economic downturn and regional debt crisis continue to limit disposable wealth, the largest driver of the breast implant market. As a result of the current economic climate, manufacturers are employing more aggressive competitive tactics in order to preserve revenues and capture market share. Smaller competitors have recently shown some pricing declines, indicating a willingness to compete on price.

“The most rapid changes in this market have come from the 2010 departure of Poly Implant Prothèse, known as PIP, the French company whose products are now banned from the breast implant market,” said MRG Marketrack Product Manager Jennifer Thomas. “PIP was in the top three to five competitors in several European national markets just a few years ago. Governments are debating recommendations and funding for replacing potentially hazardous PIP implants for women who received them. Germany and France have explicitly recommended removal. The likely result of explants and re-implants are another opportunity for market competition among the surviving competitors, particularly in France, where PIP had substantial share.”

The long-term results of the publicity surrounding the hazardous PIP implants are still to be seen. If the result is a decline in procedure volumes, as patients become reluctant to trust implants of any kind, the industry as a whole will suffer. However, if there is a flight to the perceived safety and quality of recognized brands, big name companies such as Allergan and Mentor will benefit, while smaller names will have relatively greater difficulty in competing.

These results can be found in MRG’s European Breast Implant Marketrack. This study tracks breast implant usage, market sizes and market shares across Europe, including EU5 (France, Germany, Italy, Spain and the United Kingdom), the Nordic region (Denmark, Finland, Norway and Sweden) and Belgium and the Netherlands on a quarterly basis.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]
or
Millennium Research Group
Alex Jablokow, 617-599-8613
[email protected]

KEYWORDS:   Europe  North America  Canada

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Other Health  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.